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Abstract
 
During their final differentiation or maturation, dendritic cells (DCs) redistribute their major his-
tocompatibility complex (MHC) class II products from intracellular compartments to the plasma
membrane. Using cells arrested in the immature state, we now find that DCs also regulate the
initial intracellular formation of immunogenic MHC class II–peptide complexes. Immature DCs
internalize the protein antigen, hen egg lysozyme (HEL), into late endosomes and lysosomes rich
in MHC class II molecules. There, despite extensive colocalization of HEL protein and MHC
class II products, MHC class II–peptide complexes do not form unless the DCs are exposed to
 
inflammatory mediators such as tumor necrosis factor 
 
a
 
, CD40 ligand, or lipoplolysaccharide. The
control of T cell receptor (TCR) ligand formation was observed using the C4H3 monoclonal
antibody to detect MHC class II–HEL peptide complexes by flow cytometry and confocal mi-
croscopy, and with HEL-specific 3A9 transgenic T cells to detect downregulation of the TCR
upon MHC–peptide encounter. Even the binding of preprocessed HEL peptide to MHC class II
 
is blocked in immature DCs, including the formation of C4H3 epitope in MHC class II compart-
 
ments, suggesting an arrest to antigen presentation at the peptide-loading step, rather than an
enhanced degradation of MHC class II–peptide complexes at the cell surface, as described in pre-
vious work. Therefore, the capacity of late endosomes and lysosomes to produce MHC class II–
peptide complexes can be strictly controlled during DC differentiation, helping to coordinate an-
tigen acquisition and inflammatory stimuli with formation of TCR ligands. The increased ability
 
of maturing DCs to load MHC class II molecules with antigenic cargo contributes to the 
 
.
 
100-
fold enhancement of the subsequent primary immune response observed when immature and
mature DCs are compared as immune adjuvants in culture and in mice.
Key words: dendritic cell • maturation • MHC class II–peptide complex • lysosome • 
inﬂammation
 
Introduction
 
Dendritic cells (DCs),
 
1
 
 perhaps the most potent and versa-
tile of APCs, capture foreign antigens encountered in pe-
ripheral tissues, process the antigens into peptides bound to
MHC molecules, and migrate to lymphoid organs for pre-
sentation of the MHC–peptide complexes to T lympho-
cytes (1, 2). In keeping with this critical role in stimulating
antigenically naive T cells, the immunostimulatory activity
of DCs is carefully regulated, with the cells exhibiting at
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Abbreviations used in this paper: 
 
CD40L, CD40 ligand; DC, dendritic cell;
HEL, hen egg lysozyme; 
 
3
 
H-TdR, [
 
3
 
H]thymidine; Ii chain, MHC class II–
associated invariant chain; MIICs, MHC class II compartments. 
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least two functionally distinct states. Resting or immature
DCs, corresponding to those found in the periphery, gen-
erally have a high capacity for endocytosis and thus for
antigen uptake (3–6), but a low capacity for binding and
stimulating T cells. Mature DCs, on the other hand, are
generated from immature cells by exposure to proinflam-
matory agents (TNF, LPS), physical trauma, or T cell sur-
face molecules (CD40 ligand [CD40L]; references 7–10).
Mature DCs exhibit a limited capacity for endocytosis, but
they are exceptional at stimulating T cells (3–10), typically
presenting immunogenic peptides derived from previously
encountered antigens. The capacity of mature DCs to acti-
vate naive T cells reflects several developmentally regu-
lated changes. These include upregulation of CD40, CD80,
and CD86 costimulatory molecules (11, 12), release of cyto-
kines like IL-12 (13, 14), resistance to IL-10–mediated im-
munosuppression (15), and expression of new chemokine
receptors like CCR7 that guide DCs to the T cell areas (16–
19). Importantly, mature DCs upregulate surface MHC class
II and functional MHC class II–peptide complexes that en-
gage the TCR (20, 21).
This increased expression of MHC class II molecules is
known to reflect at least two alterations (20, 21). First,
newly synthesized MHC class II molecules become re-
routed intracellularly. Instead of being transported to lyso-
somes for sequestration or degradation, the MHC class II is
targeted to the plasma membrane. One underlying mecha-
nism involves the activation of the APC-restricted protease
cathepsin S, which in turn mediates the post–Golgi com-
plex cleavage of the MHC class II–associated invariant (Ii)
chain. These events facilitate the early release of Ii chain
from MHC class II 
 
a
 
/
 
b
 
 dimers, allowing surface transport
rather than intracellular retention due to lysosomal target-
ing/endocytosis signals found in the Ii chain cytoplasmic
domain (22). The cleavage of Ii could also free the MHC
class II binding site for antigen binding (23, 24), but this
level of regulation has not yet been demonstrated in matur-
ing DCs. Second, because of the downregulation of en-
docytosis that occurs concomitant with maturation, there is
an increase in the surface residence time, half-life, and thus
overall expression of any MHC class II–peptide complexes
that do reach the plasma membrane (20, 21).
To further delineate the mechanism underlying the critical
conversion of DCs from immature sentinels to mature immu-
nostimulatory cells, we made use of a monoclonal antibody,
C4H3, that allows the direct visualization of a peptide–MHC
class II complex formed from a hen egg lysozyme (HEL) pep-
tide and an I-A
 
k
 
 
 
a
 
/
 
b
 
 dimer (25, 26). We also identified condi-
tions that allow the in vitro maintenance and rapid manipula-
tion of immature bone marrow–derived DCs. Together, these
approaches revealed an additional and more fundamental level
at which the development of antigen presentation capacity is
controlled during DC maturation, the actual formation of
MHC class II–peptide complexes within MHC class II–rich
lysosomal compartments. We show that this maturation is a
major control for T cell priming by DCs in vivo, a new find-
ing that impacts upon their optimal use for immunotherapy in
humans (27–30).
 
Materials and Methods
 
Mice.
 
CBA/J and lipid A–unresponsive C3H/HeJ female
mice were purchased from The Jackson Laboratory or from Japan
SLC, and were used at 6–8 wk of age.
 
Dendritic Cells.
 
DCs were grown in RPMI 1640 containing
5% FCS from bone marrow progenitors with mouse rGM-CSF
(31) at 10 ng/ml (gift of Dr. Y. Yamaguchi, Kirin, Maebashi, Ja-
pan), or the supernatant (3% vol/vol) from J558L cells transduced
with murine (m)GM-CSF (from Dr. A. Lanzavecchia, Basel In-
stitute, Basel, Switzerland). At day 6, the cultures contained many
aggregates of immature DCs loosely attached to the monolayer.
To mature the DCs, we added either TNF (100–500 U/ml;
Dainippon Pharmaceutical Co.), CD40L (a baculovirus prepara-
tion provided by Drs. M. Nussenzweig and Y. Choi, The Rock-
efeller University, New York, NY), or LPS (1–10 ng/ml, 
 
Escher-
ichia coli
 
 type 0111.B4; Sigma Chemical Co.), or we simply
transferred the cells to a fresh vessel at 
 
,
 
5 
 
3 
 
10
 
6
 
 cells/ml (31).
 
Antigen Administration. 
 
HEL (Sigma Chemical Co.) was added
to immature bone marrow DCs at 30–3,000 
 
m
 
g/ml for 0.5–24 h.
Also, explants of ear skin (epidermis and dermis) were bathed in
3,000 
 
m
 
g/ml, after which the DCs were examined within epider-
mal sheets or as cells that had emigrated from the explants (32,
33). The dominant HEL 46-61 peptide for I-A
 
k
 
 was synthesized
at Yale University Medical School. OVA was used as control
protein. HEL protein uptake was visualized with 1B12 mono-
clonal IgG2b anti-HEL antibody, provided by Dr. P. Allen
(Washington University, St. Louis, MO), and MHC class II–HEL
peptide complexes visualized with C4H3 rat IgG2b monoclonal
antibody (25, 26). Antibody staining, including that with isotype
controls (PharMingen), was assessed on a FACScan™ (Becton
Dickinson) or by immunofluorescence confocal microscopy. DCs
were identified by labeling for the I-E MHC II product (14-4-4S
antibody), and mature DCs by high expression of CD86 (GL-1;
PharMingen).
 
Removal of Endotoxin Activity. 
 
To deplete much of the endo-
toxin activity (limulus amebocyte assay; BioWhittaker) in HEL
preparations, HEL at 10 mg/ml was adsorbed with tachyplesin
III–conjugated Sepharose CL (34; Kuttsuclean™; Maruha Corp.)
according to the manufacturer’s instructions.
 
Antigen Presentation Assays. 
 
Presentation of HEL to T cells
was monitored using purified CD4
 
1
 
 T cells from 3A9 TCR
transgenic mice (35) provided by Dr. M. Davis (Stanford Univer-
sity, Palo Alto, CA). These T cells are specific for the same MHC
class II–peptide complex recognized by the C4H3 antibody.
Graded doses of DCs that were exposed to HEL minus or plus a
maturation stimulus were applied to 250,000 CD4
 
1
 
 transgenic T
cells in 96-well flat-bottomed microtest plates in RPMI 1640
containing 5% FCS. The DCs were fixed beforehand in 0.75%
paraformaldehyde for 30 min on ice. CD4
 
1
 
 T cells were enriched
by negative selection from spleen and lymph node suspensions by
coating other cells with antibodies (TIB 120 anti–MHC class II,
TIB 207 anti-CD8, HB198 F4/80 anti-macrophage, 6B2 anti-
B220, and NK1.1) and depleting them with sheep anti–rat Ig
Dynabeads
 
®
 
 M-450 (No. 110.08; Dynal). T cell responses were
monitored at 5 h by a decrease in TCR (V
 
b
 
8) or increase in
CD69 (PharMingen antibodies), or at 30–42 h by [
 
3
 
H]thymidine
(
 
3
 
H-TdR) uptake at 1 
 
m
 
Ci/ml. Data are from triplicate cultures
with SE 
 
,
 
10% of the mean. For presentation studies in vivo with
adoptively transferred DCs, immature cells were cultured with
graded doses of HEL overnight with or without CD40L or LPS as
a maturation stimulus. The DCs were harvested, washed, and in-
jected subcutaneously at a dose of 200,000 DCs per paw of non-
transgenic mice. 5 d later, the draining lymph nodes were re- 
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moved, dissociated into single cell suspensions, and cultured at
300,000 cells per flat-bottomed microtest well in Click’s medium
with 0.75% mouse serum and graded doses of HEL. 
 
3
 
H-TdR up-
take was measured at 52–64 h to document the extent of CD4
 
1
 
 T
cell priming.
 
Results
 
Synergistic Effects between the Exposure to Antigen and a Mat-
uration Stimulus in the Formation of MHC Class II–Peptide
Complexes.
 
Immature DCs from day 6 GM-CSF–stimu-
lated marrow cultures (31) were exposed for various periods
of time to increasing concentrations of HEL. The formation
of the C4H3 epitope, i.e., MHC class II–HEL peptide
complexes, was monitored by FACS
 
®
 
. Strong signals were
not seen at the DC surface after a 3-h exposure to HEL, but
were present after 18–24 h (pulse data; Fig. 1 A). The for-
mation of C4H3 was proportional to the added dose of
HEL; signals became detectable at 30 
 
m
 
g/ml (not shown).
Immature DCs only had to be pulsed a short time with
 
HEL to develop strong C4H3 signals 1 d later (pulse–chase
data; Fig. 1 A). For example, a 3-h pulse of 3,000 
 
m
 
g/ml
HEL followed by an 18-h chase in its absence gave compa-
rable C4H3 staining to continuous culture in HEL.
However, the addition of HEL to immature DCs not
only led to the appearance of C4H3 epitope, but also to
maturation. Most MHC class II–positive DCs began to ex-
press high levels of CD40 and CD86 and higher levels of
surface MHC class II compared with cultures not incu-
bated with HEL (Fig. 1 B). Although initially surprising,
HEL-induced maturation could be explained by the fact
that 1 mg/ml HEL contained high endotoxin activity,
1–10 ng/ml in the limulus endotoxin assay, as reported
(36). Likewise, simple transfer of the immature DCs to a
fresh culture dish, a procedure that is used to enhance the
expansion of residual proliferating cells in the culture, en-
hanced maturation (Fig. 1 B; references 21 and 31). There-
fore, in all subsequent experiments, a new invertebrate ad-
sorbent termed Kuttsuclean™ was used to remove most
endotoxin (34) without decreasing HEL content, and we
Figure 1. Formation of MHC–
peptide complexes by bone mar-
row–derived DCs. (A) DCs in
bone marrow cultures were
pulsed with 3,000 mg/ml of HEL
for the times indicated on the
x-axis, washed, and assayed im-
mediately for C4H3 staining (pulse)
or chased until 21 h of total cul-
ture (pulse–chase). The y-axis dis-
plays increases in mean fluores-
cence index (MFI) for I-E1 DCs
relative to cultures in the absence
of HEL protein. (B) A maturation
stimulus is present in commercial
preparations of HEL. Immature
6-d marrow cultures were main-
tained for one additional day in the absence of another stimulus or in the presence of the stimuli listed on the top, including transfer to a new vessel (right).
Maturation was monitored at the level of surface MHC class II expression (y-axis) and surface CD40 and CD86 (x-axis), with anti-CD8 antibody used as a
nonreactive isotype control.
Figure 2. Antigen and a maturation stim-
ulus synergize to form MHC–peptide com-
plexes. (A) Day 6 bone marrow cultures
from CBA/J mice were cultured for 24 h in
the absence of HEL or LPS, with either
HEL (1,000 mg/ml) or LPS (5 ng/ml), or
with both. The HEL had been passed over a
Kuttsuclean™ adsorbent. Left: anti-CD8
isotype control. Middle: CD86 marker for
DC maturation, with the percentage of ma-
ture CD86-rich cells indicated. Right:
mean fluorescent index (MFI) of the C4H3
signal on I-E1 DCs. Similar results were ob-
tained using C3H/HeJ DCs matured with
CD40L in three experiments. (B) Cells
were pulsed with HEL protein for 3 h, and
then washed before adding the maturation
stimulus where indicated for a chase period
of 21 h. (C) Cells were pulsed with prepro-
cessed HEL peptide for 3 h, and then
washed before adding LPS where indicated
for a chase period of 21 h. 
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compared immature and maturing cells in cultures that
were not subcultured from their initial wells.
The addition of Kuttsuclean™-treated HEL did not in-
duce DC maturation, as indicated by a lack of generation
of CD86
 
1
 
 cells or the increased expression of surface MHC
class II (I-E and I-A). Importantly, only small amounts of
C4H3 epitope appeared at the plasma membrane (Fig. 2 A).
DCs incubated under these conditions could be kept in the
immature state for at least 3–4 d. In prior work (20, 21),
immature DCs exhibited a slow but spontaneous rate of
maturation, and some formation of the SDS stable dimers
suggestive of MHC–peptide complex formation. The mat-
uration stimuli (LPS, TNF, CD40L, and transfer to a new
culture vessel) induced an increase in CD86
 
1
 
 cells, and
some increase in background C4H3 staining (Fig. 2 A),
presumably because the higher levels of I-A on mature
DCs presented self-peptides that cross-reacted with HEL
peptide (25, 26). Nevertheless, the combination of HEL
and a maturation stimulus was markedly synergistic, with
very high C4H3 levels being observed on most DCs in
 
.
 
10 similar experiments (Fig. 2 A).
 
Mechanisms Underlying the Synergism of Antigen and a Mat-
uration Stimulus in Controlling MHC Class II–Peptide Com-
plex Formation.
 
To establish that the maturation stimulus
was not merely increasing uptake of HEL, we applied the
antigen as a pulse for 3 h, and then washed the cells before
the addition of LPS or CD40L. The synergistic effect of
the maturation stimulus remained apparent in all three ex-
periments (Fig. 2 B), indicating that maturation functioned
to enhance HEL processing and/or formation of C4H3-reac-
tive MHC class II–HEL peptide complexes. In a compan-
ion study (37), we found that the HEL-pulsed DCs can be
cultured for at least 48 h before adding a maturation stimu-
lus, but the cells still display C4H3 at levels 
 
.
 
50% of that
seen when the addition of LPS or CD40L is not delayed.
Therefore, maturation stimuli increase the formation of
TCR ligands, and do not simply reduce their degradation.
To determine if maturation was acting only at the level of
antigen processing/proteolysis, we pulsed DCs for 3 h with
preprocessed HEL peptide (that is able to bind directly to
I-A
 
k
 
), washed the cells, and then cultured without or with a
maturation stimulus. The latter was again required for MHC–
Figure 3. Localization of HEL
protein and MHC class II–peptide
complexes in DCs. The procedure
was the same as described in the leg-
end to Fig. 2, but here the forma-
tion of MHC class II–peptide was
monitored at 3 and 24 h by immuno-
fluorescence confocal microscopy.
On the left are CBA DCs cultured
in HEL only, and on the right are
cells cultured with HEL 1 LPS.
Representative cells are shown fol-
lowing double labeling in green for
the HEL antigen, either HEL pro-
tein with 1B12 antibody or I-Ak/
HEL MHC-peptide complexes with
C4H3. Red stain identifies the lyso-
somal membrane glycoprotein lyso-
somal-associated membrane protein
2. Identical red staining is seen with
H-2M or MHC class II. The results
are representative of .10 experi-
ments, and of experiments with
both HEL protein and preprocessed
HEL peptide. The maturation-
induced C4H3 signal at 24 h is
shown for a well-spread cell, but in
optical sections through thicker
cells, C4H3 stain is almost entirely
along the cell perimeter. 
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peptide complex formation (Fig. 2 C), indicating that pep-
tide access to the MHC class II binding site was controlled
by the maturation process.
Conceivably, maturation might control C4H3 epitope
expression by controlling the delivery of HEL to the MHC
class II compartments (MIICs) that are thought to be critical
for MHC–peptide complex formation. Therefore, we per-
formed immunofluorescence confocal microscopy to local-
ize C4H3 in the absence or presence of a maturation stimu-
lus. As shown in Fig. 3 (left), immature DCs accumulated
endotoxin-free HEL protein in intracellular compartments,
 
as detected with 1B12 antibody to intact HEL. These struc-
tures were positive for MHC class II, Ii chain, and the pep-
tide editing H-2M product, and were judged to be late en-
dosomes and lysosomes by staining for the lysosomal
membrane glycoprotein, lgp-B (or lysosomal-associated
membrane protein [LAMP]-2; Fig. 3). Despite the fact that
HEL was delivered to MIICs, no C4H3 staining was ob-
served even after incubations of up to 24 h in HEL (Fig. 3)
or preprocessed HEL peptide (not shown). Also, no C4H3
staining was found when only a maturation stimulus was
given (LPS or CD40L; not shown), in spite of the weak sig-
nals on the FACS
 
®
 
 (Fig. 2).
Quite a different result was obtained in cells exposed to
HEL together with a maturation stimulus (Fig. 3, right). As
before, HEL protein was found in MIICs, but in all the
DCs, abundant C4H3 stain could also be observed within
MIICs. After 3 h or less in HEL, C4H3 staining was only
observed within MIICs (Fig. 3). At 24 h, most of the
MHC–peptide complexes were on the cell surface (Fig. 3),
as described previously for the distribution of MHC class II
products in maturing DCs (20, 21). Similar findings were
made in pulse–chase experiments, carried out as in Fig. 2 B;
when a maturation stimulus was applied after the pulse with
HEL antigen, MHC–peptide complexes began to form in
MIICs within 3 h, and were later found on the cell surface.
 
MIICs as a Site for MHC–Peptide Complex Formation in the
Epidermis.
 
To visualize the intracellular sites for MHC
class II–peptide formation in DCs in intact tissue, we stud-
ied epidermal DCs that mature when they migrate from
skin (32, 33) via afferent lymphatics (38, 39). Endotoxin-
containing HEL was injected into the ear dermis or added
to skin explants in vitro. Epidermal sheets and the emigrated
DCs were then examined. 5 h after injection, clear cut cola-
beling for C4H3 and the lysosomal marker H-2M was ob-
served within all DCs in the epidermal sheets (Fig. 4 A), but
not in DCs given control OVA protein. At 22 h, the C4H3
was on the surface of most DCs (Fig. 4 A). DCs that emi-
grated from explants into the medium during 2 d of culture
had a mature CD86
 
11
 
 phenotype (Fig. 4 B) and stained
strongly for C4H3 if HEL had been added to the explant. If
HEL was added to mature DCs after emigration, C4H3
staining was not seen (Fig. 4 B). Thus, immature endocytic
epidermal DCs form MHC–peptide complexes in MIICs in
vivo, but mature DCs are no longer able to do so.
 
Functional Consequences of the Synergism between Antigen
and a Maturation Stimulus: In Vitro Studies of Antigen Presen-
tation to Naive TCR Transgenic T Cells.
 
In vitro antigen
presentation assays were used to assess the functional con-
sequences of DC maturation and increased amounts of
MHC–peptide complexes. We used naive 3A9 TCR trans-
genic T cells (35) specific for the same I-A
 
k
 
–HEL peptide
complex recognized by C4H3 antibody. Immature, mar-
row-derived DCs were exposed for 1 d to HEL in graded
doses, to CD40L or LPS, or to both HEL and the matura-
tion stimulus. The cells were washed, fixed in paraformal-
dehyde, and added in graded doses to TCR transgenic T
cells (Fig. 5 A). Fixation ensured that the DCs did not ma-
ture during the culture with T cells. HEL-pulsed imma-
Figure 4. Formation of MHC–peptide complexes in immature DCs in
situ. (A) Explants of CBA ear skin were bathed in 3,000 mg/ml LPS con-
taining HEL for 5 or 22 h. At each time point, epidermal sheets were
prepared and double labeled for the H-2M marker of MIICs (green) and
for C4H3 epitope (red). The sheets were examined by two-color immu-
nofluoresence confocal microscopy. The effect of a maturation stimulus
could not be examined in vivo, because simple injection of PBS could
induce some DCs to mature. (B) Explants of ear skin were cultured in
the absence or presence of HEL for 48 h, and then the emigrated cells
were doubled labeled for CD86 to identify the DCs (arrows) and C4H3.
Some of the cells that emigrated in the absence of HEL were then cul-
tured for 2 d in the presence of HEL before similar FACS® studies. The
MFI for CD861 cells is given in each panel. 
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ture DCs only weakly stimulated the TCR transgenic T
cells, but when the DCs had been exposed to both HEL
and CD40L or LPS, strong T cell stimulation ensued (Fig.
5 A). With mature DCs, the DNA synthesis (
 
3
 
H-TdR up-
take) that we observed early in the response (day 2) with
low DC to T cell ratios (1:60–1:2,000) was 
 
.
 
2 
 
3
 
 10
 
5
 
 cpm
per well under standard assay conditions, and it was pro-
portional to the level of MHC class II–peptide on the DCs
(Fig. 5 A).
The poor T cell–stimulatory activity of immature DCs
could reflect a lack of either TCR ligand (“signal one”) or
costimulatory molecules such as CD86 (“signal two”). The
use of the C4H3 antibody for the detection of signal one
was likely to be insensitive relative to that of the TCR.
For example, an exposure of DCs to 30 
 
m
 
g/ml of HEL
was necessary to detect MHC–peptide complex formation
with C4H3 antibody, whereas an exposure to 10 
 
m
 
g/ml
was sufficient to saturate T cell stimulation at a DC/T cell
ratio of 1:60 (Fig. 5 A, left). To assess MHC class II–pep-
tide complexes at the level of the TCR, we used the crite-
rion of TCR downregulation. Prior studies have shown
that the TCR is cleared from the cell surface upon en-
counter of MHC–peptide complexes; this downregulation
appears not to require a special type of APC or the pres-
ence of costimulatory molecules on that APC (40, 41).
Using staining with anti-V
 
b
 
8 antibody, we monitored ex-
pression of the TCR on 3A9 cells cultured for 5 h with
mature or immature HEL-pulsed DCs, prepared exactly as
described in the legend to Fig. 5 A. At all doses of HEL
studied (10–1,000 
 
m
 
g/ml), mature DCs quickly activated a
sizable fraction of the T cells, as indicated by de novo ex-
pression of the CD69 T cell activation marker. TCR
downregulation was evident on all CD69
 
1
 
 cells. In con-
trast, immature DCs induced little increase in CD69 or
decrease in TCR (Fig. 5A). We conclude that a matura-
tion stimulus is needed for DCs to form MHC class II–
peptide complexes, as assessed with B cell (C4H3 anti-
body) or T cell (the 3A9 TCR) receptors.
 
Functional Consequences of the Synergism between Antigen
and a Maturation Stimulus: In Vivo Studies of Antigen Presen-
tation to Naive Mice.
 
The above data establish a relation-
ship between maturation and the formation of immuno-
genic MHC–peptide complexes in vitro, but the relevance
of DC maturation to immunogenicity in vivo has yet to be
tested. To this end, immature DCs were incubated in
graded doses of endotoxin-free HEL with or without a
Figure 5. Antigen presenting activity of DCs in vitro after culture with graded doses of HEL, minus or plus LPS or CD40L as a maturation stimulus.
(A) Day 6 bone marrow DCs from CBA mice (top) or C3H/HeJ mice (bottom) were cultured for 20 h with graded doses of HEL (x-axis) that had been
endotoxin depleted with Kuttsuclean™. One group of cultures was matured by simultaneous addition of LPS or CD40L (closed symbols), and the other
was unstimulated (open symbols). After 20 h, the cells were harvested, washed, and fixed in paraformaldehyde to block further processing and matura-
tion. MHC–peptide complexes were quantified in terms of C4H3 staining, and are shown as mean fluorescence indices on the left. The fixed DCs were
added in graded doses (top) to 250,000 CD41 T cells from 3A9 TCR transgenic mice (specific for the same complex of I-Ak 1 HEL peptide as C4H3
antibody). 3H-TdR uptake was measured at 30–42 h. One of three similar experiments. (B) The display of TCR ligands by fixed DCs was monitored at
5 h on T cells (gated away from DCs by light scattering) by the criteria of TCR downregulation (anti-Vb8, y-axis) and CD69 upregulation (x-axis). The
DC/T cell ratio was 1:3 in the data that are shown, and the percentage of CD691 cells is indicated in each dot plot (upper right).
Figure 6. Antigen presenting activity of DCs in vivo after culture with
graded doses of HEL, minus (open symbols) or plus (closed symbols)
CD40L as a maturation stimulus. As described in the legend to Fig. 5,
graded doses of antigen (top) were used to pulse C3H/He DCs over-
night. The washed, unfixed cells were injected subcutaneously into syn-
geneic mice, 2 3 105 per paw. 5 d later, cultured draining lymph node
cells were challenged with different doses of HEL protein (x-axis), and
3H-TdR uptake measured at 42–48 h (y-axis). Data are shown as stimula-
tion relative to the background cpm in lymph nodes cultured without an-
tigen. One of three similar experiments. 
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maturation stimulus, CD40L. Unfixed DCs were then in-
jected subcutaneously into naive syngeneic mice. The ma-
ture cells were far more powerful immunogens compared
with immature cells, and priming was proportional to the
dose of HEL and MHC peptide on the DCs (Fig. 6).
When we tested T cells isolated from lymph nodes of mice
injected with mature HEL-loaded DCs, the proliferation
was 
 
.
 
100-fold more sensitive to a given dose of antigen.
If 25 
 
m
 
g of HEL was injected without DCs, T cell priming
was not seen (not shown). Therefore, maturation mark-
edly increases the adjuvant capacity of adoptively trans-
ferred DCs that have been previously pulsed with antigens
ex vivo.
 
Discussion
 
As introduced above, maturation changes DCs in many
ways that explain their potency in initiating immunity. Ma-
turing cells express surface molecules like CD40 and CD86
required for T cell expansion and cytokine synthesis (11,
12), produce high levels of IL-12 (13, 14), resist suppression
by IL-10 (15), and upregulate chemokine receptors (16–19)
that recognize chemokines produced in lymphoid organs
(42, 43). Here, a new feature of maturation has emerged, an
intensified capacity to convert endocytosed antigens to
MHC class II–peptide complexes.
There is evidence with human monocyte–derived DCs
that maturation can prolong the life span of MHC class II–
peptide complexes on the cell surface (20). However, direct
visualization of these complexes now shows that the matu-
ration process can regulate an earlier and more critical step,
the formation of TCR ligands in MIICs. The results in a
companion study (37), in which antigen-pulsed DCs can be
cultured for 48 h before forming MHC–peptide complexes
in response to a maturation stimulus, nullifies the possibility
that immature DCs are simply degrading these complexes.
MHC class II products are designed to capture antigenic
peptides from pathogens internalized by endocytosis (44,
45). Through the chaperone function of the Ii chain (46,
47) or by dileucine motifs within the cytoplasmic domain
of the class II 
 
b 
 
chain (48), MHC class II molecules are tar-
geted to acidic compartments termed MIICs (49–51).
These lysosomes contain proteases for antigen processing,
as well as HLA-DM or H-2M molecules for enhancing
peptide loading to MHC class II (52, 53). Nevertheless,
there has been little direct visualization of newly formed
MHC–peptide complexes in physiological APCs. A key
control is likely to be the uptake and delivery of antigens
into MIICs. DCs are actively endocytic at the immature
stage of development (3, 4), when they also contain nu-
merous MIICs (21, 54, 55). Both endocytosis and the
number of MIICs are decreased, and even extinguished,
upon further differentiation or maturation in response to
bacteria and TNF family members. Here, we have studied
DCs frozen at the immature stage (Materials and Methods).
These DCs internalize antigens into MIICs, but surpris-
ingly, MHC class II–peptide complexes fail to form effi-
ciently until an inflammatory stimulus is applied.
Because cathepsin S controls Ii chain proteolysis (56) and
the availability of MHC class II molecules for peptide load-
ing, one of the possible mechanisms explaining these data is
that maturation downregulates the cathepsin S inhibitor,
cystatin C (22). Consistent with this, we observed a striking
inability to load the MHC class II products of immature
DCs with peptide, until a maturation stimulus was applied.
Similar events could take place in vivo, because when the
maturation stimulus LPS in HEL preparations is given to
mice, there is an accumulation of DCs with high levels of
C4H3 in T cell areas (36). The control of MHC class II–
peptide formation could also be exerted at other levels,
e.g., the acidity of the endocytic system and the function of
additional proteases.
In companion studies, we show that MHC class II–pep-
tide complexes, newly formed in the late endosomes or ly-
sosomes of DCs, selectively accumulate, together with
CD86 costimulators, into specialized vesicular carriers be-
fore their delivery to the plasma membrane (37). We term
these MHC class II–positive lysosome-negative vesicles
“CIIVs”, for class II vesicles. Remarkably, the MHC class
II–peptide complexes and CD86 costimulators remain in
clusters at the cell surface. This juxtaposition may explain
the potent naive T cell stimulation of DCs that we now
observe, even when the cells are fixed in a low dose of
formaldehyde (Fig. 5).
Our findings, especially the in vivo priming results in
Fig. 6, are relevant to the optimal use of DCs for immuno-
therapy in humans (27–30). It is not only valuable to de-
liver antigens to DCs, but also to mature the cells to in-
crease successful antigen processing and to provide other
valuable physiological features cited above. The data also
relate to the potential of DCs to control the alternative
outcome of antigen deposition, tolerance rather than im-
munity. Antigen-bearing immature DCs may induce non-
responsiveness, according to views that tolerance develops
if T cells recognize antigen in the absence of costimulation
(57, 58). We would question whether immature DCs, at
least the cells that we have generated here from bone mar-
row progenitors, can directly tolerize, since requisite MHC
class II–peptides do not form efficiently. Instead, the re-
cently described transfer of antigen (59) from immature pe-
ripheral DCs to resident lymph node–processing DCs may
generate the MHC class II peptide complexes needed by
tolerizing APCs that are found in lymph nodes (60). The
mature cells that we generate ex vivo and that efficiently
prime T cells in vivo (Fig. 6) express high levels of CD86
costimulators. We are intrigued by the fact that in the ap-
parent absence of maturation stimuli, lymph node DCs that
are implicated in tolerance (60) can express high levels of
MHC–peptide but relatively low levels of CD86 (61).
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